What was the safety profile of ribociclib (Kisqali) in the phase 3 NATALEE trial (NCT03701334)? JHAVERI: Neutropenia is the most common toxicity. All-grade neutropenia [occurred in] 62% [of patients] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback